CIPHER PHARMACEUTICALS INC (CPH.CA) Stock Fundamental Analysis
TSX:CPH • CA17253X1050
14.57 CAD
-0.11 (-0.75%)
Last: Feb 19, 2026, 07:00 PM
Taking everything into account, CPH scores 7 out of 10 in our fundamental rating. CPH was compared to 33 industry peers in the Pharmaceuticals industry. CPH has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. CPH is not priced too expensively while it is growing strongly. Keep and eye on this one! These ratings could make CPH a good candidate for growth and quality investing.
1. Profitability
1.1 Basic Checks
- CPH had positive earnings in the past year.
- In the past year CPH had a positive cash flow from operations.
- In the past 5 years CPH has always been profitable.
- Each year in the past 5 years CPH had a positive operating cash flow.
1.2 Ratios
- CPH has a Return On Assets of 11.77%. This is amongst the best in the industry. CPH outperforms 90.91% of its industry peers.
- CPH has a better Return On Equity (15.23%) than 87.88% of its industry peers.
- CPH's Return On Invested Capital of 7.23% is amongst the best of the industry. CPH outperforms 87.88% of its industry peers.
- CPH had an Average Return On Invested Capital over the past 3 years of 8.42%. This is in line with the industry average of 8.74%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.77% | ||
| ROE | 15.23% | ||
| ROIC | 7.23% |
ROA(3y)22.3%
ROA(5y)18.43%
ROE(3y)26.05%
ROE(5y)22.41%
ROIC(3y)8.42%
ROIC(5y)14.92%
1.3 Margins
- With an excellent Profit Margin value of 34.68%, CPH belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
- CPH's Profit Margin has improved in the last couple of years.
- CPH's Operating Margin of 25.51% is amongst the best of the industry. CPH outperforms 87.88% of its industry peers.
- CPH's Operating Margin has declined in the last couple of years.
- Looking at the Gross Margin, with a value of 74.32%, CPH belongs to the top of the industry, outperforming 93.94% of the companies in the same industry.
- CPH's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 25.51% | ||
| PM (TTM) | 34.68% | ||
| GM | 74.32% |
OM growth 3Y-26.62%
OM growth 5Y-14.41%
PM growth 3Y-0.73%
PM growth 5Y19.11%
GM growth 3Y-4.61%
GM growth 5Y-3.67%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so CPH is destroying value.
- CPH has more shares outstanding than it did 1 year ago.
- Compared to 5 years ago, CPH has less shares outstanding
- The debt/assets ratio for CPH is higher compared to a year ago.
2.2 Solvency
- CPH has an Altman-Z score of 6.32. This indicates that CPH is financially healthy and has little risk of bankruptcy at the moment.
- With an excellent Altman-Z score value of 6.32, CPH belongs to the best of the industry, outperforming 93.94% of the companies in the same industry.
- The Debt to FCF ratio of CPH is 0.45, which is an excellent value as it means it would take CPH, only 0.45 years of fcf income to pay off all of its debts.
- With an excellent Debt to FCF ratio value of 0.45, CPH belongs to the best of the industry, outperforming 93.94% of the companies in the same industry.
- A Debt/Equity ratio of 0.12 indicates that CPH is not too dependend on debt financing.
- With a decent Debt to Equity ratio value of 0.12, CPH is doing good in the industry, outperforming 66.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.12 | ||
| Debt/FCF | 0.45 | ||
| Altman-Z | 6.32 |
ROIC/WACC0.85
WACC8.5%
2.3 Liquidity
- A Current Ratio of 1.30 indicates that CPH should not have too much problems paying its short term obligations.
- CPH's Current ratio of 1.30 is on the low side compared to the rest of the industry. CPH is outperformed by 66.67% of its industry peers.
- A Quick Ratio of 0.98 indicates that CPH may have some problems paying its short term obligations.
- CPH has a Quick ratio of 0.98. This is comparable to the rest of the industry: CPH outperforms 45.45% of its industry peers.
- CPH does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.3 | ||
| Quick Ratio | 0.98 |
3. Growth
3.1 Past
- CPH shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.76%.
- The Earnings Per Share has been growing by 12.97% on average over the past years. This is quite good.
- The Revenue has grown by 89.17% in the past year. This is a very strong growth!
- CPH shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 8.25% yearly.
EPS 1Y (TTM)4.76%
EPS 3Y14.06%
EPS 5Y12.97%
EPS Q2Q%2000%
Revenue 1Y (TTM)89.17%
Revenue growth 3Y14.99%
Revenue growth 5Y8.25%
Sales Q2Q%23.75%
3.2 Future
- The Earnings Per Share is expected to grow by 20.66% on average over the next years. This is a very strong growth
- CPH is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 27.91% yearly.
EPS Next Y52.6%
EPS Next 2Y-7.46%
EPS Next 3Y20.66%
EPS Next 5YN/A
Revenue Next Year50.96%
Revenue Next 2Y26.89%
Revenue Next 3Y27.91%
Revenue Next 5YN/A
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 16.19, the valuation of CPH can be described as correct.
- Based on the Price/Earnings ratio, CPH is valued cheaply inside the industry as 81.82% of the companies are valued more expensively.
- The average S&P500 Price/Earnings ratio is at 27.09. CPH is valued slightly cheaper when compared to this.
- The Price/Forward Earnings ratio is 26.99, which means the current valuation is very expensive for CPH.
- 63.64% of the companies in the same industry are more expensive than CPH, based on the Price/Forward Earnings ratio.
- CPH's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 27.98.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.19 | ||
| Fwd PE | 26.99 |
4.2 Price Multiples
- CPH's Enterprise Value to EBITDA is on the same level as the industry average.
- CPH's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. CPH is cheaper than 78.79% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.98 | ||
| EV/EBITDA | 13.89 |
4.3 Compensation for Growth
- CPH's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The excellent profitability rating of CPH may justify a higher PE ratio.
- A more expensive valuation may be justified as CPH's earnings are expected to grow with 20.66% in the coming years.
PEG (NY)0.31
PEG (5Y)1.25
EPS Next 2Y-7.46%
EPS Next 3Y20.66%
5. Dividend
5.1 Amount
- No dividends for CPH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
TSX:CPH (2/19/2026, 7:00:00 PM)
14.57
-0.11 (-0.75%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)03-12 2026-03-12
Inst Owners1.29%
Inst Owner ChangeN/A
Ins Owners3.62%
Ins Owner ChangeN/A
Market Cap368.33M
Revenue(TTM)50.05M
Net Income(TTM)17.36M
Analysts80
Price Target19.58 (34.39%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)51.24%
Min EPS beat(2)36.14%
Max EPS beat(2)66.34%
EPS beat(4)2
Avg EPS beat(4)14.52%
Min EPS beat(4)-37.21%
Max EPS beat(4)66.34%
EPS beat(8)5
Avg EPS beat(8)34.73%
EPS beat(12)9
Avg EPS beat(12)113.55%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.76%
Min Revenue beat(2)-6.01%
Max Revenue beat(2)2.48%
Revenue beat(4)1
Avg Revenue beat(4)-1.18%
Min Revenue beat(4)-6.01%
Max Revenue beat(4)2.48%
Revenue beat(8)2
Avg Revenue beat(8)-0.16%
Revenue beat(12)3
Avg Revenue beat(12)1.53%
Revenue beat(16)3
Avg Revenue beat(16)-1.19%
PT rev (1m)6.52%
PT rev (3m)7.26%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-6.06%
EPS NY rev (1m)0.72%
EPS NY rev (3m)10.32%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-5.54%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.98%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.19 | ||
| Fwd PE | 26.99 | ||
| P/S | 5.37 | ||
| P/FCF | 8.98 | ||
| P/OCF | 8.96 | ||
| P/B | 2.36 | ||
| P/tB | 11.77 | ||
| EV/EBITDA | 13.89 |
EPS(TTM)0.9
EY6.18%
EPS(NY)0.54
Fwd EY3.71%
FCF(TTM)1.62
FCFY11.13%
OCF(TTM)1.63
OCFY11.16%
SpS2.71
BVpS6.18
TBVpS1.24
PEG (NY)0.31
PEG (5Y)1.25
Graham Number11.18
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.77% | ||
| ROE | 15.23% | ||
| ROCE | 10.05% | ||
| ROIC | 7.23% | ||
| ROICexc | 7.75% | ||
| ROICexgc | 33.36% | ||
| OM | 25.51% | ||
| PM (TTM) | 34.68% | ||
| GM | 74.32% | ||
| FCFM | 59.76% |
ROA(3y)22.3%
ROA(5y)18.43%
ROE(3y)26.05%
ROE(5y)22.41%
ROIC(3y)8.42%
ROIC(5y)14.92%
ROICexc(3y)14.84%
ROICexc(5y)25.78%
ROICexgc(3y)32.35%
ROICexgc(5y)N/A
ROCE(3y)11.69%
ROCE(5y)20.72%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y-55.02%
ROICexc growth 5Y-33.6%
OM growth 3Y-26.62%
OM growth 5Y-14.41%
PM growth 3Y-0.73%
PM growth 5Y19.11%
GM growth 3Y-4.61%
GM growth 5Y-3.67%
F-Score7
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.12 | ||
| Debt/FCF | 0.45 | ||
| Debt/EBITDA | 0.67 | ||
| Cap/Depr | 1.2% | ||
| Cap/Sales | 0.17% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 152.24% | ||
| Profit Quality | 172.34% | ||
| Current Ratio | 1.3 | ||
| Quick Ratio | 0.98 | ||
| Altman-Z | 6.32 |
F-Score7
WACC8.5%
ROIC/WACC0.85
Cap/Depr(3y)670.82%
Cap/Depr(5y)415.05%
Cap/Sales(3y)80.33%
Cap/Sales(5y)48.9%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4.76%
EPS 3Y14.06%
EPS 5Y12.97%
EPS Q2Q%2000%
EPS Next Y52.6%
EPS Next 2Y-7.46%
EPS Next 3Y20.66%
EPS Next 5YN/A
Revenue 1Y (TTM)89.17%
Revenue growth 3Y14.99%
Revenue growth 5Y8.25%
Sales Q2Q%23.75%
Revenue Next Year50.96%
Revenue Next 2Y26.89%
Revenue Next 3Y27.91%
Revenue Next 5YN/A
EBIT growth 1Y29.19%
EBIT growth 3Y-15.61%
EBIT growth 5Y-7.36%
EBIT Next Year140.38%
EBIT Next 3Y50.84%
EBIT Next 5YN/A
FCF growth 1Y98.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y99.32%
OCF growth 3Y12.28%
OCF growth 5Y19.77%
CIPHER PHARMACEUTICALS INC / CPH.CA FAQ
What is the ChartMill fundamental rating of CIPHER PHARMACEUTICALS INC (CPH.CA) stock?
ChartMill assigns a fundamental rating of 7 / 10 to CPH.CA.
What is the valuation status for CPH stock?
ChartMill assigns a valuation rating of 6 / 10 to CIPHER PHARMACEUTICALS INC (CPH.CA). This can be considered as Fairly Valued.
What is the profitability of CPH stock?
CIPHER PHARMACEUTICALS INC (CPH.CA) has a profitability rating of 8 / 10.
What are the PE and PB ratios of CIPHER PHARMACEUTICALS INC (CPH.CA) stock?
The Price/Earnings (PE) ratio for CIPHER PHARMACEUTICALS INC (CPH.CA) is 16.19 and the Price/Book (PB) ratio is 2.36.
How financially healthy is CIPHER PHARMACEUTICALS INC?
The financial health rating of CIPHER PHARMACEUTICALS INC (CPH.CA) is 7 / 10.